Y. Mossé

发表

The genetic landscape of high-risk neuroblastoma

Steven J. M. Jones, Adam Kiezun, Shaun D. Jackman, 2013, Nature Genetics.

Phenotype Restricted Genome-Wide Association Study Using a Gene-Centric Approach Identifies Three Low-Risk Neuroblastoma Susceptibility Loci

Joseph T. Glessner, J. Glessner, H. Hakonarson, 2011, PLoS genetics.

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

W. Gerald, E. Rappaport, J. Maris, 2006, Cancer research.

Molecular Therapy for Neuroblastoma

J. Maris, Y. Mossé, 2010 .

Chromosome 1p and 11q deletions and outcome in neuroblastoma.

Hiroyuki Shimada, Cynthia Winter, John M Maris, 2005, The New England journal of medicine.

Germline PHOX2B mutation in hereditary neuroblastoma.

E. Rappaport, J. Maris, A. Carlisle, 2004, American journal of human genetics.

Identification of ALK as a major familial neuroblastoma predisposition gene

John M. Maris, Nicholas J. Schork, Ali Torkamani, 2008, Nature.

RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma

Cynthia Winter, Sharon J Diskin, John M Maris, 2011, Proceedings of the National Academy of Sciences.

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

S. Groshen, J. Maris, K. Matthay, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differences in Genomic Profiles and Outcomes between Thoracic and Adrenal Neuroblastoma.

J. Maris, K. Matthay, S. Diskin, 2019, Journal of the National Cancer Institute.

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.

Rachel A. Kudgus, S. Groshen, R. Hawkins, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project

F. Berthold, K. Matthay, P. Ambros, 2014, Pediatric blood & cancer.

Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

S. Groshen, R. Hawkins, J. Maris, 2012, Clinical Cancer Research.

Copy number variation at 1q21.1 associated with neuroblastoma

Sharon J. Diskin, John M. Maris, Struan F. A. Grant, 2009, Nature.

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.

Nazneen Rahman, Joseph T. Glessner, Hakon Hakonarson, 2008, The New England journal of medicine.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

Gregory P. Way, Jo Lynne Rokita, D. Haussler, 2019, Cell reports.

Genomic landscape of 261 childhood cancer patient-derived xenograft models

Gregory P. Way, Jo Lynne Rokita, D. Haussler, 2019, bioRxiv.

Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Patricia Greninger, C. Benes, B. Hu, 2021, Molecular Cancer Therapeutics.

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

Daniel Martinez, Bruce R. Pawel, P. Raman, 2019, Science Translational Medicine.

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

K. Norga, K. Wilner, Martha Donoghue, 2021, European journal of cancer.

Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells

E. Rappaport, P. O'dwyer, Y. Mossé, 2014, Front. Oncol..

Computational algorithms for in silico profiling of activating mutations in cancer

R. Radhakrishnan, Y. Mossé, M. Lemmon, 2019, Cellular and Molecular Life Sciences.

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Rachel A. Kudgus, S. Groshen, J. Maris, 2018, Clinical Cancer Research.

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

J. Maris, D. Teachey, C. Ahern, 2012, Clinical Cancer Research.

MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial

S. Groshen, R. Hawkins, J. Maris, 2012 .

Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma.

B. Weber, A. King, J. Maris, 2003, The Lancet. Oncology.

Safety and efficacy of tandem 131I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma

J. Maris, H. Zhuang, Y. Mossé, 2011, Pediatric blood & cancer.

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

J. Maris, B. Teicher, P. Houghton, 2020, Pediatric blood & cancer.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

J. Orange, J. Christensen, S. Asgharzadeh, 2011, Oncogene.

Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake

J. Maris, Y. Mossé, J. Edgar, 2021, JCO precision oncology.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

David Haussler, Jacob Pfeil, Olena Morozova Vaske, 2019, Cell reports.

Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma

J. Maris, B. Teicher, Y. Mossé, 2018, Clinical Research (Excluding Clinical Trials).

ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.

E. Rappaport, J. Maris, Y. Mossé, 2003, Cancer Research.

Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT‐751: A report from the Children's Oncology Group (ANBL0621)

J. Maris, G. Gordon, J. Gurney, 2014, Pediatric Blood & Cancer.

Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era.

B. Weber, J. Maris, J. Greshock, 2005, Cancer letters.

Prevalence and functional consequence of PHOX2B mutations in neuroblastoma

J. Maris, Y. Mossé, N. Wasserman, 2008, Oncogene.

Thrown for a Loop: Awakening BORIS to Evade ALK Inhibition Therapy.

Y. Mossé, Esther R Berko, 2019, Cancer cell.

Computational algorithms for in silico profiling of activating mutations in cancer

R. Radhakrishnan, Y. Mossé, M. Lemmon, 2019, Cellular and Molecular Life Sciences.

Chromosome arm 11q deletion predicts for neuroblastoma outcome: A Children’s Oncology Group study

J. Maris, K. Matthay, E. Attiyeh, 2005 .

Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study.

M. Lim, C. Ahern, P. Adamson, 2012 .

Erratum: Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy (Genome Research (2009) 19 (276-283))

Marc A. Attiyeh, Sharon J. Diskin, John M. Maris, 2009 .

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

U. McDermott, M. Garnett, A. Dastur, 2016, Cancer cell.

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

S. Seaman, J. Maris, B. Teicher, 2021, Clinical Cancer Research.

Inhibition of ALK Signaling for Cancer Therapy

J. Maris, Y. Mossé, A. Wood, 2009, Clinical Cancer Research.

Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression

K. Cole, J. Maris, S. Diskin, 2007, Genes, chromosomes & cancer.

Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma

G. Caponigro, Nanxin Li, Jennifer L. Harris, 2016, Clinical Cancer Research.

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Ravi Radhakrishnan, Peter J. Huwe, E. Rappaport, 2014, Cancer cell.

Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma

J. Orange, J. Christensen, S. Asgharzadeh, 2012, Oncogene.

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

Nazneen Rahman, Sharon J. Diskin, John M. Maris, 2009, Nature Genetics.

Clinical utility of custom-designed NGS panel testing in pediatric tumors

Marilyn M. Li, P. Raman, J. Maris, 2019, Genome Medicine.

Retinoblastoma and Neuroblastoma Predisposition and Surveillance

W. Foulkes, A. Nakagawara, L. Diller, 2017, Clinical Cancer Research.

A Functional Screen Identifies miR-34a as a Candidate Neuroblastoma Tumor Suppressor Gene

Sharon J. Diskin, John M. Maris, K. Cole, 2008, Molecular Cancer Research.

Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers

S. Knapp, M. Roussel, K. Shokat, 2021, Cancer Research.

A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)

D. Teachey, P. Houghton, R. Lock, 2019, Clinical Cancer Research.

Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children’s Oncology Group phase 1 consortium study (ADVL1212)

K. Wilner, P. Adamson, F. Balis, 2020, Cancer Chemotherapy and Pharmacology.

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

M. Lim, K. Wilner, P. Adamson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

J. Maris, M. Lim, K. Wilner, 2013, The Lancet. Oncology.

A Phase I Pharmacologic Study of Necitumumab (imc-11f8), a Fully Human Igg1 Monoclonal Antibody the Alk/ros1 Inhibitor Pf-06463922 Overcomes Primary Resistance to Crizotinib in Alk-driven Neuroblastoma

H. Zou, Y. Mossé, M. Lemmon, 2022 .

Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma

Huaqing Zhao, John M Maris, K. Cole, 2011, Science Translational Medicine.

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

Nazneen Rahman, Sharon J. Diskin, John M. Maris, 2011, Nature.

Abstract 3867: Understanding the neuroblastoma predisposition signal at chromosome 2q35: Identification of the β-BARD1 isoform as an oncogenic driver

K. Cole, E. Rappaport, M. Devoto, 2010 .

Detection of Single-Copy Chromosome 17q Gain in Human Neuroblastomas Using Real-Time Quantitative Polymerase Chain Reaction

Yael Mosse, John M Maris, J. Maris, 2003, Modern Pathology.

Targeting ALK in neuroblastoma—preclinical and clinical advancements

Y. Mossé, E. Carpenter, 2012, Nature Reviews Clinical Oncology.

Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity.

H. Hakonarson, K. Cole, Eva Dizin, 2012, Cancer research.

Therapeutics , Targets , and Chemical Biology Common Variation at BARD 1 Results in the Expression of an Oncogenic Isoform That In fl uences Neuroblastoma Susceptibility and Oncogenicity

H. Hakonarson, K. Cole, Eva Dizin, 2012 .

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome

P. Raman, I. Ostrovnaya, J. Maris, 2016, PLoS genetics.

A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study

A. Naranjo, S. Grupp, K. Matthay, 2021, Pediatric blood & cancer.

Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.

A. Naranjo, J. Gastier-Foster, D. von Allmen, 2021, Transplantation and cellular therapy.

Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma.

J. Maris, Y. Mossé, R. Bagatell, 2019, International journal of radiation oncology, biology, physics.

The ALK / ROS 1 inhibitor PF-06463922 overcomes primary 1 resistance to crizotinib in ALK-driven neuroblastoma 2 3

H. Zou, Y. Mossé, M. Lemmon, 2015 .

Cancer Therapy : Clinical Phase I Study of Vincristine , Irinotecan , and 131 I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma : A New Approaches to Neuroblastoma Therapy Trial

S. Groshen, R. Hawkins, J. Maris, 2012 .

Heterozygosity mapping for human dominant trait variants

J. Ott, S. Leal, M. Lathrop, 2019, Human Mutation.

Cortical processing of respiratory occlusion stimuli in children with central hypoventilation syndrome.

J. Maris, I. Colrain, C. Marcus, 2008, American journal of respiratory and critical care medicine.

Effect of sleep stage on breathing in children with central hypoventilation.

J. Maris, I. Colrain, C. Marcus, 2008, Journal of applied physiology.

High‐resolution detection and mapping of genomic DNA alterations in neuroblastoma

Adam A. Margolin, Joel Greshock, Cynthia Winter, 2005, Genes, chromosomes & cancer.

Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13.

M. Urbanek, T. Rebbeck, J. Maris, 2002, Cancer research.

Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma

P. Raman, Y. Mossé, C. Reynolds, 2015, Clinical Cancer Research.

Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma

H. Hakonarson, M. Devoto, C. Specchia, 2011, Human Heredity.

MEKing Retinoids Work Better

J. Maris, Y. Mossé, 2010 .

Letters to the Editor No " Bias " toward the Null Hypothesis in Most Conventional Multipoint Nonparametric Linkage Analyses Comparison of Linkage Statistics Analyses Using All 200 Families and Using Only the 147 Informative Families

E. Rappaport, J. Maris, A. Carlisle, 2004 .

Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy.

Marc A. Attiyeh, Sharon J. Diskin, John M. Maris, 2008, Genome research.

Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)

K. Wilner, P. Adamson, F. Balis, 2021, Clinical Cancer Research.

Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies

Y. Mossé, Yael P Mossé, 2015, Clinical Cancer Research.

Bresler Found in Neuroblastoma Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants

K. Cole, J. Maris, J. Christensen, 2011 .

Molecular Pathways Inhibition of ALK Signaling for Cancer Therapy

J. Maris, Y. Mossé, A. Wood, 2009 .

Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation

R. Radhakrishnan, Y. Mossé, M. Lemmon, 2021, Proceedings of the National Academy of Sciences.

Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas

P. White, Y. Mossé, G. Brodeur, 2008, Oncogene.

STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments.

Christian J Stoeckert, Joel Greshock, Tara L. Naylor, 2006, Genome research.

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium

F. Balis, Y. Mossé, C. Minard, 2016, Cancer Chemotherapy and Pharmacology.

Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: A New Approaches to Neuroblastoma Consortium study.

S. Groshen, J. Maris, K. Matthay, 2020 .

CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data

John Quackenbush, John M. Maris, Adam A. Margolin, 2005, Bioinform..

Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma

K. Matthay, J. Courtier, Y. Mossé, 2015, British Journal of Cancer.

Title Phase I / II study of 131 I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma Permalink

K. Matthay, J. Courtier, Y. Mossé, 2015 .

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

J. Maris, Y. Mossé, M. Lemmon, 2023, Nature communications.

Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma

J. Maris, B. Teicher, K. Isse, 2022, Cancer research communications.

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

S. Groshen, J. Maris, K. Matthay, 2023, Nature Medicine.

Erratum: Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma (Oncogene (2012) 31 (4859-4867) DOI: 10.1038/onc.2011.647)

J. Orange, J. Christensen, S. Asgharzadeh, 2012 .

Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.

E. Rappaport, J. Maris, S. Diskin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma.

Marilyn M. Li, J. Maris, Y. Mossé, 2022, Cancer discovery.

Clinical utility of custom-designed NGS panel testing in pediatric tumors

Marilyn M. Li, P. Raman, J. Maris, 2019, Genome Medicine.

Identification of genomic DNA signatures predicting relapse in low- and intermediate-risk neuroblastoma using a case control design and high-density SNP genotyping: A Children's Oncology Group (COG) study

J. Maris, S. Diskin, E. Attiyeh, 2007 .

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

D. Haussler, D. Wheeler, P. Raman, 2019, Cell reports.

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.

W. Gerald, E. Rappaport, J. Maris, 2006, Cancer research.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.

Nancy R. Zhang, Elizabeth H. Williams, Joshua F. McMichael, 2020, Cell.

aberrations across multiple array-CGH experiments STAC : A method for testing the significance of DNA copy number data

Tara L. Naylor, B. Weber, C. Stoeckert, 2006 .

A phase I study of Aurora kinase A inhibitor LY3295668 erbumine as a single agent and in combination in patients with relapsed/refractory neuroblastoma.

J. Maris, Y. Mossé, A. Lithio, 2020 .